Fmr LLC Decreases Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Fmr LLC reduced its position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 11.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,378,819 shares of the company’s stock after selling 541,541 shares during the period. Fmr LLC owned approximately 6.21% of ORIC Pharmaceuticals worth $44,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. First Turn Management LLC increased its position in shares of ORIC Pharmaceuticals by 38.1% during the 2nd quarter. First Turn Management LLC now owns 1,515,960 shares of the company’s stock valued at $10,718,000 after purchasing an additional 418,389 shares during the last quarter. Millennium Management LLC grew its position in ORIC Pharmaceuticals by 297.4% during the second quarter. Millennium Management LLC now owns 782,299 shares of the company’s stock valued at $5,531,000 after buying an additional 585,447 shares during the period. Dimensional Fund Advisors LP increased its holdings in ORIC Pharmaceuticals by 190.2% during the second quarter. Dimensional Fund Advisors LP now owns 466,662 shares of the company’s stock valued at $3,299,000 after buying an additional 305,860 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in ORIC Pharmaceuticals by 152.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company’s stock worth $4,205,000 after acquiring an additional 247,863 shares during the period. Finally, Monaco Asset Management SAM boosted its stake in shares of ORIC Pharmaceuticals by 132.0% during the 2nd quarter. Monaco Asset Management SAM now owns 301,650 shares of the company’s stock worth $2,133,000 after acquiring an additional 171,650 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals Stock Performance

ORIC stock opened at $9.90 on Friday. The company has a market capitalization of $698.64 million, a PE ratio of -5.50 and a beta of 1.13. ORIC Pharmaceuticals, Inc. has a one year low of $6.33 and a one year high of $16.65. The company’s fifty day moving average price is $9.47 and its 200-day moving average price is $9.36.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.01). On average, research analysts predict that ORIC Pharmaceuticals, Inc. will post -1.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Monday, November 4th. Oppenheimer reduced their price target on ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. Stifel Nicolaus initiated coverage on shares of ORIC Pharmaceuticals in a report on Friday, September 6th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Monday, September 23rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $18.29.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.